Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis

Joint Bone Spine

Volumn 81, Issue 3, 2014, Pages 215-221

  Che, Helene ^a   Lukas, Cedric ^a   Morel, Jacques ^a   Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Herpes zoster; Meta analysis; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTICLE; DISEASE REGISTRY; DRUG SAFETY; FOLLOW UP; HERPES SIMPLEX; HERPES ZOSTER; HOSPITALIZATION; HUMAN; INCIDENCE; META ANALYSIS; PROPHYLAXIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMATIC REVIEW; VIRUS REACTIVATION; INFECTION RISK; JAPANESE (PEOPLE); VETERAN; VIRUS ACTIVATION;

HERPES ZOSTER; META-ANALYSIS; RHEUMATOID ARTHRITIS; TNF INHIBITORS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HERPES ZOSTER; HERPESVIRIDAE INFECTIONS; HUMANS; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901412275     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.07.009     Document Type: Article

References (37)

1. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
2. Galloway J.B., Hyrich K.L., Mercer L.K., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50:124-131.
3. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
4. Galloway J.B., Mercer L.K., Moseley A., et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013, 72:229-234.
5. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005, 352:2266-2267.
6. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4:26-33.
7. McDonald J.R., Zeringue A.L., Caplan L., et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009, 48:1364-1371.
8. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744.
9. Greenberg J.D., Reed G., Kremer J.M., et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69:380-386.
10. Winthrop K.L., Baddley J.W., Chen L., et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013, 309:887-895.
11. Sakai R., Komano Y., Tanaka M., et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res 2012, 64:1125-1134.
12. Perez-Zafrilla B., García Doval I., Carmona L. Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort. Ann Rheum Dis 2008, 67:327. [abstract FRI0129].
13. Titton D., Hayata A., Carvalho H., et al. Biologic register in a developing country: safety is different from european registries? The biobadabrasil first results. Ann Rheum Dis 2010, 69:717. [abstract AB0958].
14. Inanc N., Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int 2006, 27:67-71.
15. Schiff M., Keiserman M., Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
16. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum 2010, 39:327-346.
17. Botsios C., Ramonda R., Lo Nigro A., et al. Infections during tumour necrosis factor-alpha and interleukin-1 blocking therapy for rheumatoid arthritis and spondylarthropathies in daily practice. 7years experience with 726patients in a single italian academic center. Ann Rheum Dis 2008, 67:175. [abstract THU0126].
18. Tubach F., Salmon D., Lortholary O., et al. The risk of non-tuberculosis opportunistic infections is higher in patients treated with infliximab or adalimumab than in patients treated with etanercept. Results of the 3-year prospective french RATIO registry. Ann Rheum Dis 2010, 69:523. [abstract SAT0113].
19. Koike T., Harigai M., Inokuma S., et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009, 36:898-906.
20. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007, 57:1431-1438.
21. Wolfe F., Michaud K., Chakravarty E.F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006, 45:1370-1375.
22. Suarez-Almazor M.E., Belseck E., Shea B., et al. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev Online 2000, 4:CD001157.
23. García-Doval I., Pérez-Zafrilla B., Descalzo M.A., et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010, 69:1751-1755.
24. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant Therapy Study of Group. N Engl J Med 2000, 343:1594-1602.
25. Maini R.N., Breedveld F.C., Kalden J.R., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051-1065.
26. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
27. Furst D.E., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
28. Moreland L.W., Weinblatt M.E., Keystone E.C., et al. Etanercept treatment in adults with established rheumatoid arthritis: 7years of clinical experience. J Rheumatol 2006, 33:854-861.
29. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
30. Salmon-Ceron D., Tubach F., Lortholary O., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70:616-623.
31. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528.
32. Tubach F., Salmon D., Ravaud P., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60:1884-1894.
33. Serac G., Tubach F., Mariette X., et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol 2012, 132:726-729.
34. Haider A.S., Cardinale I.R., Whynot J.A., et al. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007, 12:9-15.
35. Harpaz R., Ortega-Sanchez I.R., Seward J.F., et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30.
36. Zhang J., Xie F., Delzell E., et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012, 308:43-49.
37. Veetil B.M.A., Matteson E.L., Gabriel S.E., et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based Cohort Study. Arthritis Rheum 2011, 63:S462-S463. [abstract 1187].